Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?
Executive Summary
Having lost market share in recent years to HIV regimens containing ViiV's Tivicay, will a showing of non-inferiority across four head-to-head Phase III studies give bictegravir the market edge Gilead seeks?
You may also be interested in...
Gilead's Strong HIV Quarter Plus Bictegravir May Portend Sector Dominance
Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's future growth is unclear, however, without M&A.
Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen
The latest HIV drug development news and highlights from our FDA Performance Tracker.
ViiV/Janssen Forge Two-Drug Future For HIV With SWORD Filings
The battle of the HIV giants ViiV Healthcare and Gilead Sciences continues with the first filing for a two-drug regimen for use against HIV infection in the US and EU.